Doxorubicin-eluting bead versus conventional TACE for unresectable hepatocellular carcinoma: A meta-analysis

Hepato-Gastroenterology

Volumn 60, Issue 124, 2013, Pages 813-820

  Gao, Sheng ^a,b   Yang, Zhe ^a,b,c   Zheng, Zhiyun ^a,b   Yao, Jia ^a,b   Deng, Min ^d   Xie, Haiyang ^a,b,c   Zheng, Shusen ^a,b,c   Zhou, Lin ^a,b,c  

^a ZHEJIANG UNIVERSITY   (China)

^b KEY LABORATORY OF ORGAN TRANSPLANTATION   (China)

^c ZHEJIANG UNIVERSITY SCHOOL OF MEDICINE   (China)

^d ZHEJIANG UNIVERSITY   (China)

Author keywords

Conventional TACE; Doxorubicin eluting bead TACE; Unresectable hepatocellular carcinoma

Indexed keywords

DOXORUBICIN;

ARTICLE; CANCER CONTROL; CANCER GROWTH; CHEMOEMBOLIZATION; COCHRANE LIBRARY; CONTROLLED CLINICAL TRIAL (TOPIC); DRUG DELIVERY SYSTEM; DRUG ELUTING BEAD; EMBASE; EVIDENCE BASED MEDICINE; HUMAN; INOPERABLE CANCER; INTERMETHOD COMPARISON; LIVER CELL CARCINOMA; MEDLINE; META ANALYSIS; MULTICENTER STUDY (TOPIC); OUTCOME ASSESSMENT; PRIORITY JOURNAL; PUBLICATION; SYSTEMATIC REVIEW; TREATMENT RESPONSE;

ANTIBIOTICS, ANTINEOPLASTIC; CARCINOMA, HEPATOCELLULAR; CHEMOEMBOLIZATION, THERAPEUTIC; DOXORUBICIN; HUMANS; LIVER NEOPLASMS; MICROSPHERES;

EID: 84879559493     PISSN: 01726390     EISSN: None     Source Type: Journal    
DOI: 10.5754/hge121025     Document Type: Article

References (35)

1. Venook AP, Papandreou C, Furuse J, de Guevara LL: The incidence and epidemiology of hepatocellular carcinoma: a global and regional perspective. Oncologist 2010; 15Suppl4:5-13.
2. Parkin DM: Global cancer statistics in the year 2000. Lancet Oncol 2001; 2:533-543.
3. Song MJ, Park CH, Sung PS, et al.: Comparative study between dc bead(registered trademark) loaded with doxorubicin and conventional transarterial chemoembolization in the treatment of hepatocellular carcinoma in Korea. J Hepatol 2011; 54:S265.
4. Eisenhauer EA, Therasse P, Bogaerts J, et al.: New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 2009; 45:228-247.
5. El-Serag HB, Rudolph KL: Hepatocellular carcinoma: epidemiology and molecular carcinogenesis. Gastroenterology 2007;132:2557-2576. (Pubitemid 46890874)
6. Marelli L, Stigliano R, Triantos C, et al.: Transarterial therapy for hepatocellular carcinoma: Which technique is more effective? A systematic review of cohort and randomized studies. Cardiovascular and Interventional Radiology 2007; 30:6-25. (Pubitemid 44900485)
7. Colleoni M, Audisio RA, De Braud F, Fazio N, Martinelli G, Goldhirsch A: Practical considerations in the treatment of hepatocellular carcinoma. Drugs 1998; 55:367-382. (Pubitemid 28112246)
8. Llovet JM, Real MI, Montana X, et al.: Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocelluiar carcinoma: a randomised controlled trial. Lancet 2002; 359:1734-1739. (Pubitemid 34607087)
9. Lo CM, Ngan H, Tso WK, et al.: Randomized controlled trial of transarterial lipiodol chemoembolization for unresectable hepatocellular carcinoma. Hepatology 2002; 35:1164-1171. (Pubitemid 34454013)
10. de Baere T, Roche A, Amenabar JM, et al.: Liver abscess formation after local treatment of liver tumors. Hepatology 1996; 23:1436-1440. (Pubitemid 26181226)
11. Ernst O, Sergent G, Mizrahi D, Delemazure O, Paris JC, L'Hermine C: Treatment of hepatocellular carcinoma by transcatheter arterial chemoembolization: comparison of planned periodic chemoembolization and chemoembolization based on tumor response. AJR Am J Roentgenol 1999; 172:59-64. (Pubitemid 29028431)
12. Venook AP, Stagg RJ, Lewis BJ, et al.: Chemoembolization for hepatocellular carcinoma. J Clin Oncol 1990; 8:1108-1114. (Pubitemid 20200200)
13. Lewis AL, Gonzalez MV, Lloyd AW, et al.: DC bead: in vitro characterization of a drug-delivery device for transarterial chemoembolization. J Vasc Interv Radiol 2006; 17:335-342. (Pubitemid 44341453)
14. Lewis AL, Taylor RR, Hall B, Gonzalez MV, Willis SL, Stratford PW: Pharmacokinetic and safety study of doxorubicin-eluting beads in a porcine model of hepatic arterial embolization. J Vasc Interv Radiol 2006; 17:1335-1343. (Pubitemid 44259017)
15. Tang Y, Taylor RR, Gonzalez MV, Lewis AL, Stratford PW: Evaluation of irinotecan drug-eluting beads: a new drug-device combination product for the chemoembolization of hepatic metastases. J Control Release 2006; 116:e55-56.
16. Lewis AL, Gonzalez MV, Leppard SW, et al.: Doxorubicin eluting beads - 1: effects of drug loading on bead characteristics and drug distribution. J Mater Sci Mater Med 2007; 18:1691-1699. (Pubitemid 47224923)
17. Taylor RR, Tang Y, Gonzalez MV, Stratford PW, Lewis AL: Irinotecan drug eluting beads for use in chemoembolization: in vitro and in vivo evaluation of drug release properties. Eur J Pharm Sci 2007; 30:7-14. (Pubitemid 44908921)
18. Therasse P, Arbuck SG, Eisenhauer EA, et al.: New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000; 92:205-216.
19. Moher D, Liberati A, Tetzlaff J, Altman DG: Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. BMJ 2009; 339:b2535.
20. Higgins JPT GS: Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0[updated March 2011]. The Cochrane Colloboration. 2009; Available from www.cochrane-handbook.org.
21. Deeks JJ HJ, Altman DG (eds.). Chapter 9: Analysing data and undertaking meta-analyses. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 510[updated March 2011]. 2009;The Cochrane Collaboration, 2009. Available from www.cochrane-handbook.org.
22. DerSimonian R, Laird N: Meta-analysis in clinical trials. Control Clin Trials 1986; 7:177-188. (Pubitemid 17189972)
23. Galbraith RF: A note on graphical presentation of estimated odds ratios from several clinical trials. Stat Med 1988; 7:889-894.
24. Altman DG, Bland JM: Interaction revisited: the difference between two estimates. BMJ 2003; 326:219. (Pubitemid 36143396)
25. Egger M, Davey Smith G, Schneider M, Minder C: Bias in meta-analysis detected by a simple, graphical test. BMJ 1997; 315:629-634. (Pubitemid 27387172)
26. Begg CB, Mazumdar M: Operating characteristics of a rank correlation test for publication bias. Biometrics 1994; 50:1088-1101.
27. Song MJ, Park CH, Kim JD, et al.: Drug-eluting bead loaded with doxorubicin versus conventional Lipiodol-based transarterial chemoembolization in the treatment of hepatocellular carcinoma: A case-control study of Asian patients. European J Gastroenterol Hepatol 2011; 23:521-527.
28. Dhanasekaran R, Kooby DA, Staley CA, Kauh JS, Khanna V, Kim HS: Comparison of conventional transarterial chemoembolization (TACE) and chemoembolization with doxorubicin drug eluting beads (DEB) for unresectable hepatocelluar carcinoma (HCC). J Surg Oncol 2010; 101:476-480.
29. Ferrer Puchol MD, la Parra C, Esteban E, et al.: Comparison of doxorubicin-eluting bead transarterial chemoembolization (DEB-TACE) with conventional transarterial chemoembolization (TACE) for the treatment of hepatocellular carcinoma. Radiologia 2011; 53:246-253.
30. Lammer J, Malagari K, Vogl T, et al.: Prospective randomized study of doxorubicin-eluting-bead embolization in the treatment of hepatocellular carcinoma: results of the PRECISION V study. Cardiovasc Intervent Radiol 2010; 33:41-52.
31. Lencioni R, Malagari K, Vogl T, et al.: A randomised phase II trial of a drug eluting bead in the treatment of hepatocellular carcinoma by transcatheter arterial chemoembolization. Hepatology 2009; 50:1076A.
32. Sacco R, Bargellini I, Bertini M, et al.: Conventional versus doxorubicin-eluting bead transarterial chemoembolization for hepatocellular carcinoma. J Vasc Interv Radiol 2011; 22:1545-1552.
33. van Malenstein H, Maleux G, Vandecaveye V, et al.: A randomized phase II study of drug-eluting beads versus transarterial chemoembolization for unresectable hepatocellular carcinoma. Onkologie 2011; 34:368-376.
34. Vogl TJ, Zangos S, Balzer JO, et al.: Transarterial chemoembolization (TACE) in hepatocellular carcinoma: Technique, indication and results. Rofo-Fortschr Gebiet Rontgenstrahlen Bildgeb Verfahr 2007; 179:1113-1126. (Pubitemid 350155118)
35. Martin R, Irurzun J, Munchart J, et al.: Optimal technique and response of doxorubicin beads in hepatocellular cancer: bead size and dose. Korean J Hepatol 2011; 17:51-60.